CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Paul G Richardson,Albert Oriol,Tiziana Civardi,Jessica Katz,Zehua Zhou,Richard Leblanc,Cesar Rodriguez,Ralph Wäsch,Suzanne Trudel,Darrell White,Aurore Perrot,Marc-Steffen Raab,Tara Gregory,Nizar J Bahlis,Manisha Lamba,Irwindeep Sandhu,Meletios A Dimopoulos,Teresa Peluso,Paulo Maciag,Michael Amatangelo,Noopur Raje ,Enrique M Ocio

doi:10.1182/blood-2021-147812

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Paul G Richardson, Albert Oriol + Show 20 more

Open Access

https://doi.org/10.1182/blood-2021-147812

Copy DOI

#Equity Holder In Publicly-traded Company #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Full Text